Document is current
Any future updates will be listed below
-
Authors
Hung, King L. https://orcid.org/0000-0002-3662-4662
Luebeck, Jens https://orcid.org/0000-0003-4391-979X
Dehkordi, Siavash R.
Colón, Caterina I.
Li, Rui
Wong, Ivy Tsz-Lo
Coruh, Ceyda
Dharanipragada, Prashanthi
Lomeli, Shirley H.
Weiser, Natasha E. https://orcid.org/0000-0001-9971-2961
Moriceau, Gatien
Zhang, Xiao https://orcid.org/0000-0003-1706-2868
Bailey, Chris
Houlahan, Kathleen E.
Yang, Wenting
González, Rocío Chamorro https://orcid.org/0000-0002-5653-7259
Swanton, Charles https://orcid.org/0000-0002-4299-3018
Curtis, Christina
Jamal-Hanjani, Mariam https://orcid.org/0000-0003-1212-1259
Henssen, Anton G. https://orcid.org/0000-0003-1534-778X
Law, Julie A. https://orcid.org/0000-0001-7472-7753
Greenleaf, William J. https://orcid.org/0000-0003-1409-3095
Lo, Roger S. https://orcid.org/0000-0002-5337-5004
Mischel, Paul S. https://orcid.org/0000-0002-4560-2211
Bafna, Vineet https://orcid.org/0000-0002-5810-6241
Chang, Howard Y. https://orcid.org/0000-0002-9459-4393
- License Information
-
More Information
Article History
Received: 28 October 2021
Accepted: 22 August 2022
First Online: 17 October 2022
Competing interests
: H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, Cartography Biosciences and Orbital Therapeutics, and an advisor of 10x Genomics, Arsenal Biosciences and Spring Discovery. V.B. is a co-founder, paid consultant and science advisory board member and has equity interest in Boundless Bio and Abterra. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. P.M. is a co-founder and advisor of Boundless Bio. R.S.L. reports research and clinical trial support from Merck, Pfizer, BMS and OncoSec. J.L. receives compensation as a consultant for Boundless Bio. The remaining authors declare no competing interests.
